Skip to main content

Table 3 Changes in HIT-6 headache disability categories after three and six erenumab treatments

From: A prospective real-world analysis of erenumab in refractory chronic migraine

 Baseline (N = 162) N (%)Month 3 (N = 100) N (%)Month 6 (N = 73) N (%)
Severe impact (60–78)156 (96%)68 (68%)43 (59%)
Substantial impact (56–59)5 (3%)3 (3%)14 (19%)
Some impact (50–55)1 (1%)15 (15%)11 (16%)
Little or no impact (< 48)0 (0%)14 (14%)5 (6%)
  1. HIT-6, headache impact test-6; N, number
\